R&D Clinical Trials Round-Up: July/August 2026 While the volume of announcements hit a mid-year slump, July and August still produced an exciting array of updates across the drug development arena.
Oncology Sponsored Establishing ctDNA as a validated primary surrogate endpoint Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
Oncology Bridging the cancer drug development gap: AI-driven precisio... Functional precision oncology gives physicians the data they need to make better decisions about each patient’s care.
Oncology From promise to practice: What must happen next for genetic ... The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.
Digital The role of AI technologies in precision oncology By focusing on assistance to the front-line oncologist, AI can enable improved diagnosis, clinical trials, and timely, accurate decision making.
News Now Iktos teams up with Pierre Fabre in oncology As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.